avelumab + NKTR-255

Avelumab + NKTR-255 is a combination therapy under clinical investigation for cancer immunotherapy, specifically being evaluated in advanced urothelial carcinoma and other solid and hematologic tumors. **Avelumab** is a human monoclonal antibody that acts as a checkpoint inhibitor targeting PD-L1 (programmed death-ligand 1), thereby enhancing the immune system's ability to recognize and kill cancer cells. **NKTR-255** is a polymer-conjugated recombinant human interleukin-15 (IL-15) receptor agonist that stimulates the proliferation and activation of natural killer (NK) cells and CD8+ T cells, potentially enhancing anti-tumor immune activity and improving lymphocyte recovery after immunosuppressive therapies such as chemoradiation. The combination aims to synergize checkpoint inhibition with potent immune cell expansion for improved anti-cancer efficacy[2][3][4][5].